Aug 07, 2019 / 01:30PM GMT
Jason Mills - Canaccord Genuity - Analyst
We've got standing room only, not surprising for this company. Again, my name is Jason Mills; I am the senior medical devices analyst at Canaccord. Welcome and thank you for attending our conference. Again, continuing a fairly vibrant discussion here, medtech morning, with one of the fastest-growing companies in medtech not only today but over the last two-plus years, almost three years since your IPO, right, Kevin?
Kevin King - iRhythm Technologies, Inc. - President & CEO
Sure.
Jason Mills - Canaccord Genuity - Analyst
So, we're very happy to have iRhythm. Kevin King is the CEO. We also have Dan Wilson who's a new member of the management team. I know him from a previous life, but good to have you here, Dan.
And we can maybe try to take a few questions. Given the size of the audience there's obviously a lot of interest in iRhythm, but I am going to kick it off with Kevin. And I'd like to give you the opportunity to do what you probably do in a slide, at least to
iRhythm Technologies Inc at Canaccord Genuity Growth Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
